Commercialisation of Desferal® in Brazil, in partnership with Mitem Pharma

In partnership with Mitem Pharma, we are strengthening access to essential haematology treatments across Brazil. The successful transfer of Desferal® from Novartis, combined with a dedicated haematology sales force and a locally tailored commercial strategy, has reinforced our growing portfolio in the region.

Improving access to Haematology treatments in Brazil

Expanding access to essential haematology treatments in Brazil requires strong local partnerships, therapeutic expertise, and a clear long-term vision. In partnership with Mitem Pharma, we are strengthening our presence in the Brazilian market and broadening access to established and trusted therapies for patients in need.

‍

Expanding our haematology portfolio

A significant milestone in this journey has been the addition of Desferal® to our growing portfolio of haematology products in Brazil. Originally developed by Novartis, Desferal® plays an important role in the management of iron overload, including in patients with sickle cell disease who require regular transfusions. Bringing this established therapy into our portfolio reinforces our commitment to supporting comprehensive haematology care.

‍

Seamless transfer of Marketing Authorisation

Through our strategic collaboration with Mitem Pharma, the Marketing Authorisation (MA) for Desferal® was successfully transferred from Novartis to Masters. This transition was carefully managed to ensure regulatory continuity, uninterrupted supply, and sustained confidence among healthcare professionals and patients.

‍

A strategy tailored to the Brazilian market

To drive sustainable growth and expand treatment options for sickle cell patients, we implemented a full sales and marketing strategy aligned with local market dynamics. This approach reflects Brazil’s healthcare structure, regional diversity, and specific patient needs. By tailoring our activities to local realities, we are able to support clinicians more effectively while strengthening market presence.

‍

Dedicated expertise and trusted relationships

Our efforts are supported by a dedicated haematology sales force with deep therapeutic knowledge and strong, long-standing relationships with reference centres and key opinion leaders (KOLs) across Brazil. These partnerships are essential to fostering clinical confidence, encouraging best practice, and ensuring that appropriate patients have access to the treatments they require.

‍

Strengthening access through partnership

Our partnership with Mitem Pharma reflects a shared commitment to improving access to high-quality haematology treatments in Brazil. By combining regulatory expertise, commercial focus, and strong stakeholder engagement, we are helping to expand treatment options and support better outcomes for patients nationwide.

‍

Read Next

Collaboration that improves treatment options for sickle cell patients in the UK

In exclusive partnership with Theravia, we are driving sustainable growth and improving nationwide access to Siklos® across the UK. Through targeted national key account management, deep NHS and haematology network expertise, and strong KOL advocacy, we are supporting specialist centres and strengthening treatment pathways for patients living with sickle cell disease. This case study explores how a focused commercial strategy, combined with disease insight and stakeholder engagement, is expanding access and delivering measurable impact in a complex healthcare environment.

Improving access to life-changing treatment for sickle cell patients in Saudi Arabia

As part of our long-term strategic partnership with Theravia, we have successfully expanded Siklos® into Saudi Arabia. This case study highlights how careful market preparation, KOL engagement, and national account management can accelerate access to essential treatments in a new territory.